Toggle Nav

AG-1295

In stock
Catalog No.
C5465
potent and selective inhibitor of PDGF receptor kinase
Grouped product items
SizePriceStock Qty
5mg
$97.00
In stock
10mg
$180.00
In stock
25mg
$376.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

IC50: 0.3-1 μM for PDGF receptor kinase in vitro and in Swiss 3T3 cells

AG-1295 is a potent and selective inhibitor of PDGF receptor kinase.

Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. PTK inhibitors specific for platelet-derived growth factor (PDGF) receptor kinase could help in the treatment of restenosis, pulmonary fibrosis, atherosclerosis and gliomas.

In vitro: The previous study investigated the effect of PDGF receptor-beta (PDGFR-β) inhibition by AG-1295 on the osteogenic differentiation of the mouse pre-osteoblastic cell line MC3T3-E1. Results showed that AG-1295 could significantly increase the alkaline phosphatase (ALP) activity and enhance the formation of mineralized nodules dose-dependently. Moreover, the treatment with AG-1295 led to the up-regulated mRNA expression of the osteogenic marker genes collagen type I, runt-related transcription factor 2, osterix, tissue-nonspecific alkaline phosphatase, as well as osteocalcin. Consistent with its effect on osteoblast differentiation, AG-1295 was also able to significantly suppress the phosphorylation of Erk1/2 in MC3T3-E1 cells [1].

In vivo: A previous animal study was designed to evaluated the possible effects of AG1295 on the development of interstitial fibrosis in rats with unilateral ureteral obstruction, monitored by ED-A+ fibronectin expression, the number of macrophages. Results showed that the i.p.treatment with AG1295 at 12 mg/kg could significantly reduce interstitial fibrosis as verified by a smaller Sirius-Red stained area and also by a reduced number of macrophages, and by the ED-A+ fibronectin deposition and the number of cells positive for α-smooth muscle actin [2].

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Zhang YY, Cui YZ, Luan J, Zhou XY, Zhang GL, Han JX.  Platelet-derived growth factor receptor kinase inhibitor AG-1295 promotes osteoblast differentiation in MC3T3-E1 cells via the Erk pathway. Biosci Trends. 2012 Jun;6(3):130-5.
[2] Ludewig D, Kosmehl H, Sommer M, Bhmer FD, Stein G.  PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res. 2000 Jan;299(1):97-103.

Chemical Properties

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt234.3
Cas No.71897-07-9
FormulaC16H14N2
SynonymsNSC 380341,Tyrphostin AG-1295
Solubility≤5mg/ml in ethanol;2mg/ml in DMSO;2.5mg/ml in dimethyl formamide
Chemical Name6,7-dimethyl-2-phenyl-quinoxaline
SDFDownload SDF
Canonical SMILESCC1=CC2=NC=C(N=C2C=C1C)C3=CC=CC=C3
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

AG-1295